{"id":"NCT05764525","sponsor":"Vivozon Pharmaceutical Inc.","briefTitle":"Efficacy and Safety of VVZ-149 Injections in Patients Undergoing Laparoscopic Colectomy","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Laparoscopic Colectomy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-07-19","primaryCompletion":"2022-11-03","completion":"2022-11-22","firstPosted":"2023-03-10","resultsPosted":"2025-02-20","lastUpdate":"2025-02-20"},"enrollment":285,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain, Postoperative","Acute Pain"],"interventions":[{"type":"DRUG","name":"VVZ-149 Injections","otherNames":["Opiranserin Injections"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"VVZ-149 Injections","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this phase 3 study is to evaluate the efficacy and safety of VVZ-149 Injections for the treatment of postoperative pain following laparoscopic colectomy.","primaryOutcome":{"measure":"Time-weighted Sum of Pain Intensity Differences for 12 Hours Post-dose (SPID 12)","timeFrame":"0-12 hours post-dose","effectByArm":[{"arm":"VVZ-149 Injections","deltaMin":26.83,"sd":1.73},{"arm":"Placebo","deltaMin":19.89,"sd":1.72}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0047"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":5,"countries":["South Korea"]},"refs":{"pmids":["39705738"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":141},"commonTop":["Nausea","Post procedural fever","Vomiting","Hypertension","Haematochezia"]}}